Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-Evidence from three different disease models: NAFLD, HCV and HIV

World Journal of Gastroenterology

Volumn 22, Issue 44, 2016, Pages 9674-9693

  Lonardo, Amedeo ^a   Ballestri, Stefano ^b   Guaraldi, Giovanni ^a   Nascimbeni, Fabio ^a   Romagnoli, Dante ^a   Zona, Stefano ^a   Targher, Giovanni ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Atherosclerosis; Cardiovascular risk; Fatty liver; Fibrosis; Hepatitis C virus; Hepatitis C associated dysmetabolic syndrome; Human immunodeficiency virus; Nonalcoholic fatty liver disease; Steatohepatitis; Steatosis; Virus associated fatty liver disease

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT;

CARDIOVASCULAR DISEASE; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; EVIDENCE BASED MEDICINE; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER FIBROSIS; MEDICAL HISTORY; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREDICTION; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HIV INFECTIONS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; VIROLOGY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84997294316     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i44.9674     Document Type: Review

References (264)

1. Petäjä EM, Yki-Järvinen H. Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review. Int J Mol Sci 2016; 17 [PMID: 27128911 DOI: 10.3390/ijms17050633]
2. Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N, Loria P. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 2006; 44: 190-196 [PMID: 16168516 DOI: 10.1016/j.jhep.2005.06.018]
3. Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res 2016; 46: 1074-1087 [PMID: 26785389 DOI: 10.1111/hepr.12656]
4. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2016; 31: 936-944 [PMID: 26667191 DOI: 10.1111/jgh.13264]
5. Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci 2016; 17: [PMID: 27231906 DOI: 10.3390/ijms17060803]
6. Guaraldi G, Stentarelli C, Orlando G, Zona S, Carli F, Ballestri S, Lonardo A, Squillace N, Loria P. Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2010; 53: 278; author reply 278-281 [PMID: 20104126 DOI: 10.1097/QAI.0b013e3181c990ed]
7. Guaraldi G, Lonardo A, Ballestri S, Zona S, Stentarelli C, Orlando G, Carli F, Carulli L, Roverato A, Loria P. Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. Arch Med Res 2011; 42: 690-697 [PMID: 22227046 DOI: 10.1016/j.arcmed.2011.12.009]
8. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]
9. Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, Loria P. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol 2014; 20: 14185-14204 [PMID: 25339806 DOI: 10.3748/wjg.v20. i39.14185]
10. Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Sacchini V, Decensi A, Veronesi U. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005; 330: 932 [PMID: 15746106 DOI: 10.1136/bmj.38391.663287.E0]
11. Lonardo A, Trande P. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. J Gastroenterol Hepatol 2000; 15: 775-782 [PMID: 10937684]
12. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]
13. Turola E, Petta S, Vanni E, Milosa F, Valenti L, Critelli R, Miele L, Maccio L, Calvaruso V, Fracanzani AL, Bianchini M, Raos N, Bugianesi E, Mercorella S, Di Giovanni M, Craxì A, Fargion S, Grieco A, Cammà C, Cotelli F, Villa E. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. Dis Model Mech 2015; 8: 1037-1046 [PMID: 26183212 DOI: 10.1242/dmm.019950]
14. Klair JS, Yang JD, Abdelmalek MF, Guy CD, Gill RM, Yates K, Unalp-Arida A, Lavine JE, Clark JM, Diehl AM, Suzuki A. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 2016; 64: 85-91 [PMID: 26919573 DOI: 10.1002/hep.28514]
15. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 2015; 47: 997-1006 [PMID: 26454786 DOI: 10.1016/j.dld.2015.08.004]
16. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of pairedbiopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1-9; quiz e39-40 [PMID: 24768810 DOI: 10.1016/j.cgh.2014.04.014]
17. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100 [PMID: 11438497]
18. Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, Chan HL, Chim AM, Woo J, Chu WC, Wong VW. Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. Am J Gastroenterol 2015; 110: 1306-1314; quiz 1315 [PMID: 26215532 DOI: 10.1038/ajg.2015.235]
19. Glass LM, Dickson RC, Anderson JC, Suriawinata AA, Putra J, Berk BS, Toor A. Total body weight loss of ? 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2015; 60: 1024-1030 [PMID: 25354830 DOI: 10.1007/s10620-014-3380-3]
20. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease-atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013; 19: 5177-5192 [PMID: 23432668]
21. Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv Ther 2016; 33: 291-319 [PMID: 26921205 DOI: 10.1007/s12325-016-0306-9]
22. Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016; 65: 1017-1025 [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012]
23. Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient-death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011; 5: 279-289 [PMID: 21476922 DOI: 10.1586/egh.11.19]
24. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815-823 [PMID: 22966992 DOI: 10.1111/apt.12046]
25. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59: 550-556 [PMID: 23665288 DOI: 10.1016/j.jhep.2013.04.027]
26. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974 [PMID: 20581244 DOI: 10.1136/gut.2009.205088]
27. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosingsteatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62: 1148-1155 [PMID: 25477264 DOI: 10.1016/j.jhep.2014.11.034]
28. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015; 149: 389-397.e10 [PMID: 25935633 DOI: 10.1053/j.gastro.2015.04.043]
29. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for diseasespecific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-1554 [PMID: 25125077 DOI: 10.1002/hep.27368]
30. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015; 47: 181-190 [PMID: 25739820 DOI: 10.1016/j.dld.2014.09.020]
31. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013; 230: 258-267 [PMID: 24075754 DOI: 10.1016/j.atherosclerosis.2013.07.052]
32. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol 2014; 20: 13306-13324 [PMID: 25309067 DOI: 10.3748/wjg.v20. i37.13306]
33. Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, Ratziu V, Lonardo A. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014; 232: 99-109 [PMID: 24401223 DOI: 10.1016/j.atheroscleros is.2013.10.030]
34. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350 [PMID: 20879883 DOI: 10.1056/NEJMra0912063]
35. Chen Y, Xu M, Wang T, Sun J, Sun W, Xu B, Huang X, Xu Y, Lu J, Li X, Wang W, Bi Y, Ning G. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis 2015; 241: 145-150 [PMID: 25988358 DOI: 10.1016/j.atherosclerosis.2015.05.002]
36. Sapmaz F, Uzman M, Basyigit S, Ozkan S, Yavuz B, Yeniova A, Kefeli A, Asilturk Z, Nazligül Y. Steatosis Grade is the Most Important Risk Factor for Development of Endothelial Dysfunction in NAFLD. Medicine (Baltimore) 2016; 95: e3280 [PMID: 27057890 DOI: 10.1097/MD.0000000000003280]
37. Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2015; 9: 629-650 [PMID: 25327387 DOI: 10.1586/17474124.2015.965143]
38. Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 2016; 65: 1136-1150 [PMID: 26477269 DOI: 10.1016/j.metabol. 2015.09.017]
39. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1724-1745 [PMID: 24587651 DOI: 10.3748/wjg.v20.i7.1724]
40. Valbusa F, Bonapace S, Grillo C, Scala L, Chiampan A, Rossi A, Zoppini G, Lonardo A, Arcaro G, Byrne CD, Targher G. Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. Medicine (Baltimore) 2016; 95: e2760 [PMID: 26886619 DOI: 10.1097/MD.0000000000002760]
41. Mantovani A, Rigamonti A, Bonapace S, Bolzan B, Pernigo M, Morani G, Franceschini L, Bergamini C, Bertolini L, Valbusa F, Rigolon R, Pichiri I, Zoppini G, Bonora E, Violi F, Targher G. Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. Diabetes Care 2016; 39: 1416-1423 [PMID: 27222503 DOI: 10.2337/dc16-0091]
42. Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol 2009; 7: 580-585 [PMID: 19418607 DOI: 10.1016/j.cgh.2009.01.001]
43. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015; 62: 1723-1730 [PMID: 26274335 DOI: 10.1002/hep.28123]
44. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016; 63: 827-838 [PMID: 26599351 DOI: 10.1002/hep.28368]
45. Sangiovanni A, Colombo M. Surveillance for hepatocellular carcinoma: a standard of care, not a clinical option. Hepatology 2011; 54: 1898-1900 [PMID: 21932397 DOI: 10.1002/hep.24684]
46. Michelini E, Lonardo A, Ballestri S, Costantini M, Caporali C, Bonati ME, Bertolotti M, Iori R, Loria P. Is cholangiocarcinoma another complication of insulin resistance: a report of three cases. Metab Syndr Relat Disord 2007; 5: 194-202 [PMID: 18370827 DOI: 10.1089/met.2006.0018]
47. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54: 463-471 [PMID: 21538440 DOI: 10.1002/hep.24397]
48. Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Aldrighetti L, Geller DA, Sempoux C, Herlea V, Popescu I, Anders R, Rubbia-Brandt L, Gigot JF, Mentha G, Pawlik TM. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg 2013; 17: 748-755 [PMID: 23355033 DOI: 10.1007/s11605-013-2149-x]
49. Sanna C, Rosso C, Marietti M, Bugianesi E. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. Int J Mol Sci 2016; 17 [PMID: 27187365 DOI: 10.3390/ijms17050717]
50. Fukuda T, Hamaguchi M, Kojima T, Hashimoto Y, Ohbora A, Kato T, Nakamura N, Fukui M. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016; 36: 275-283 [PMID: 26176710 DOI: 10.1111/liv.12912]
51. Shah RV, Allison MA, Lima JA, Bluemke DA, Abbasi SA, Ouyang P, Jerosch-Herold M, Ding J, Budoff MJ, Murthy VL. Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2015; 242: 211-217 [PMID: 26209814 DOI: 10.1016/j.atherosclerosis.2015.07.018]
52. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013; 98: 3637-3643 [PMID: 23873989 DOI: 10.1210/jc.2013-1519]
53. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649 [PMID: 21039302 DOI: 10.3109/0785 3890.2010.518623]
54. Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes. Diabetes Care 2015; 38: 1673-1679 [PMID: 26156527 DOI: 10.2337/dc15-0140]
55. Hashimoto Y, Hamaguchi M, Fukuda T, Nakamura N, Ohbora A, Kojima T, Fukui M. BMI history and risk of incident fatty liver: a population-based large-scale cohort study. Eur J Gastroenterol Hepatol 2016; 28: 1188-1193 [PMID: 27347789 DOI: 10.1097/MEG.0000000000000682]
56. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/hep.21327]
57. Leite NC, Villela-Nogueira CA, Cardoso CR, Salles GF. Nonalcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20: 8377-8392 [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377]
58. Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Sourianarayanane A, Khiyami A, Yerian L, Pai RK, Dasarathy S, McCullough AJ. Clinical spectrum of nonalcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin 2015; 3: 141-145 [PMID: 26675585 DOI: 10.1016/j.bbacli.2014.09.001]
59. Nascimbeni F, Aron-Wisnewsky J, Pais R, Tordjman J, Poitou C, Charlotte F, Bedossa P, Poynard T, Clément K, Ratziu V. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2016; 3: e000075 [PMID: 27110380 DOI: 10.1136/bmjgast-2015-000075]
60. Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The Musketeer in the Spotlight. Int J Mol Sci 2016; 17: 355 [PMID: 27005620 DOI: 10.3390/ijms17030355]
61. Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol 2015; 8: 1-9 [PMID: 25575848 DOI: 10.1007/s12328-014-0548-5]
62. Reeves HL, Zaki MY, Day CP. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Dig Dis Sci 2016; 61: 1234-1245 [PMID: 26921078 DOI: 10.1007/s10620-016-4085-6]
63. Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E. Mortality from chronic liver diseases in diabetes. Am J Gastroenterol 2014; 109: 1020-1025 [PMID: 24890439 DOI: 10.1038/ajg.2014.132]
64. Wild SH, Morling JR, McAllister DA, Kerssens J, Fischbacher C, Parkes J, Roderick PJ, Sattar N, Byrne CD. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. J Hepatol 2016; 64: 1358-1364 [PMID: 26812073 DOI: 10.1016/j.jhep.2016.01.014]
65. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443 [PMID: 21128245 DOI: 10.1002/ijc.25797]
66. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49: 600-607 [PMID: 18672311 DOI: 10.1016/j.jhep.2008.06.012]
67. Mantovani A, Ballestri S, Lonardo A, Targher G. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016; 61: 1246-1267 [PMID: 26809873 DOI: 10.1007/s10620-016-4040-6]
68. Pais R, Giral P, Khan JF, Rosenbaum D, Housset C, Poynard T, Ratziu V. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol 2016; 65: 95-102 [PMID: 27129836 DOI: 10.1016/j.jhep.2016.02.023]
69. Ampuero J, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev Esp Enferm Dig 2015; 107: 10-16 [PMID: 25603326]
70. Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-2121 [PMID: 17519430 DOI: 10.2337/dc07-0349]
71. Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, Sørensen HT. Prognosis of patients with a diagnosis of fatty liver-a registry-based cohort study. Hepatogastroenterology 2003; 50: 2101-2104 [PMID: 14696473]
72. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218 [PMID: 17277038 DOI: 10.2337/dc06-2247]
73. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13: 1579-1584 [PMID: 17461452]
74. Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009; 50: 1403-1411 [PMID: 19670414 DOI: 10.1002/hep.23135]
75. Zhou YJ, Li YY, Nie YQ, Huang CM, Cao CY. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis 2012; 13: 153-160 [PMID: 22356310 DOI: 10.1111/j.1751-2980.2011.00571.x]
76. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012; 32: 945-950 [PMID: 22299674 DOI: 10.1111/j.1478-3231.2011.02753.x]
77. Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013; 62: 352-360 [PMID: 22999011 DOI: 10.1016/j.metabol.2012.08.005]
78. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-1365 [PMID: 23175136 DOI: 10.1002/hep.26156]
79. Pisto P, Santaniemi M, Bloigu R, Ukkola O, Kesäniemi YA. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open 2014; 4: e004973 [PMID: 24650811 DOI: 10.1136/bmjopen-2014-004973]
80. Pickhardt PJ, Hahn L, Muñoz del Rio A, Park SH, Reeder SB, Said A. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. AJR Am J Roentgenol 2014; 202: 752-758 [PMID: 24660702 DOI: 10.2214/AJR.13.11367]
81. Moon SH, Hong SP, Cho YS, Noh TS, Choi JY, Kim BT, Lee KH. Hepatic FDG uptake is associated with future cardiovascular events in asymptomatic individuals with non-alcoholic fatty liver disease. J Nucl Cardiol 2015; Epub ahead of print [PMID: 26510948 DOI: 10.1007/s12350-015-0297-y]
82. Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, Norata D, Valenti L, Grigore L, Porzio M, Catapano A, Fargion S. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of followup. Atherosclerosis 2016; 246: 208-213 [PMID: 26803429 DOI: 10.1016/j.atherosclerosis.2016.01.016]
83. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103: 2263-2271 [PMID: 18684196 DOI: 10.1111/j.1572-0241.2008.02034.x]
84. Wong VW, Wong GL, Yeung JC, Fung CY, Chan JK, Chang ZH, Kwan CT, Lam HW, Limquiaco J, Chim AM, Yu CM, Chan HL. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology 2016; 63: 754-763 [PMID: 26406278 DOI: 10.1002/hep.28253]
85. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 [PMID: 16012941]
86. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238 [PMID: 19049831 DOI: 10.1016/j.cgh.2008.11.005]
87. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602 [PMID: 20014114 DOI: 10.1002/hep.23314]
88. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Nonalcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 2016; 65: 589-600 [PMID: 27212244 DOI: 10.1016/j.jhep.2016.05.013]
89. Sinn DH, Cho SJ, Gu S, Seong D, Kang D, Kim H, Yi BK, Paik SW, Guallar E, Cho J, Gwak GY. Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. Gastroenterology 2016; 151: 481-488.e1 [PMID: 27283259 DOI: 10.1053/j.gastro.2016.06.001]
90. Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC, Byrne CD. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis 2016; 246: 13-20 [PMID: 26748347 DOI: 10.1016/j.atherosclerosis.2015.12.028]
91. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016; 126: 12-22 [PMID: 26727229 DOI: 10.1172/JCI77812]
92. Wang Y, Viscarra J, Kim SJ, Sul HS. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol 2015; 16: 678-689 [PMID: 26490400 DOI: 10.1038/nrm4074]
93. Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Biernacki D, Lo M, Suman A, Weber MH, Cusi K. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. Diabetes Care 2016; 39: 632-638 [PMID: 26861926 DOI: 10.2337/dc15-1876]
94. Meex RC, Hoy AJ, Morris A, Brown RD, Lo JC, Burke M, Goode RJ, Kingwell BA, Kraakman MJ, Febbraio MA, Greve JW, Rensen SS, Molloy MP, Lancaster GI, Bruce CR, Watt MJ. Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metab 2015; 22: 1078-1089 [PMID: 26603189 DOI: 10.1016/j.cmet.2015.09.023]
95. Popov VB, Jornayvaz FR, Akgul EO, Kanda S, Jurczak MJ, Zhang D, Abudukadier A, Majumdar SK, Guigni B, Petersen KF, Manchem VP, Bhanot S, Shulman GI, Samuel VT. Secondgeneration antisense oligonucleotides against catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance. FASEB J 2016; 30: 1207-1217 [PMID: 26644352 DOI: 10.1096/fj.15-271999]
96. Sepe PS, Ohri A, Sanaka S, Berzin TM, Sekhon S, Bennett G, Mehta G, Chuttani R, Kane R, Pleskow D, Sawhney MS. A prospective evaluation of fatty pancreas by using EUS. Gastrointest Endosc 2011; 73: 987-993 [PMID: 21521567 DOI: 10.1016/j.gie.2011.01.015]
97. Ou HY, Wang CY, Yang YC, Chen MF, Chang CJ. The association between nonalcoholic fatty pancreas disease and diabetes. PLoS One 2013; 8: e62561 [PMID: 23671610 DOI: 10.1371/journal. pone.0062561]
98. Wu WC, Wang CY. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: casecontrol retrospective study. Cardiovasc Diabetol 2013; 12: 77 [PMID: 23688357 DOI: 10.1186/1475-2840-12-77]
99. Wang CY, Ou HY, Chen MF, Chang TC, Chang CJ. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. J Am Heart Assoc 2014; 3: e000297 [PMID: 24572250 DOI: 10.1161/JAHA.113.000297]
100. Uygun A, Kadayifci A, Demirci H, Saglam M, Sakin YS, Ozturk K, Polat Z, Karslioglu Y, Bolu E. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur J Intern Med 2015; 26: 37-41 [PMID: 25491010 DOI: 10.1016/j.ejim.2014.11.007]
101. Yamazaki H, Tsuboya T, Katanuma A, Kodama Y, Tauchi S, Dohke M, Maguchi H. Lack of Independent Association Between Fatty Pancreas and Incidence of Type 2 Diabetes: 5-Year Japanese Cohort Study. Diabetes Care 2016; 39: 1677-1683 [PMID: 27422578 DOI: 10.2337/dc16-0074]
102. Pezzilli R, Calculli L. Pancreatic steatosis: Is it related to either obesity or diabetes mellitus? World J Diabetes 2014; 5: 415-419 [PMID: 25126389 DOI: 10.4239/wjd.v5.i4.415]
103. Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem 2012; 81: 767-793 [PMID: 22443930 DOI: 10.1146/annurev-biochem-072909-095555]
104. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013; 43: 51-64 [PMID: 23332087 DOI: 10.1111/j.1872-034X.2012.01031.x]
105. Sharma RB, Alonso LC. Lipotoxicity in the pancreatic beta cell: not just survival and function, but proliferation as well? Curr Diab Rep 2014; 14: 492 [PMID: 24740729 DOI: 10.1007/s11892-014-0492-2]
106. Sookoian S, Gianotti TF, Rosselli MS, Burgueño AL, Castaño GO, Pirola CJ. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 2011; 218: 378-385 [PMID: 21664615 DOI: 10.1016/j.atherosclero sis.2011.05.014]
107. Käräjämäki AJ, Bloigu R, Kauma H, Kesäniemi YA, Koivurova OP, Perkiömäki J, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes. Metabolism 2016 [PMID: 27423871 DOI: 10.1016/j.metabol.2016.06.009]
108. Lawlor DA, Callaway M, Macdonald-Wallis C, Anderson E, Fraser A, Howe LD, Day C, Sattar N. Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents. J Clin Endocrinol Metab 2014; 99: E410-E417 [PMID: 24471572 DOI: 10.1210/jc.2013-3612]
109. Adams LA. NAFLD. Accurate quantification of hepatic fat-is it important? Nat Rev Gastroenterol Hepatol 2015; 12: 126-127 [PMID: 25666645 DOI: 10.1038/nrgastro.2015.23]
110. Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2015; 13: 1513-1520.e1 [PMID: 25661453 DOI: 10.1016/j.cgh.2015.01.027]
111. Soardo G, Donnini D, Domenis L, Catena C, De Silvestri D, Cappello D, Dibenedetto A, Carnelutti A, Bonasia V, Pagano C, Sechi LA. Oxidative stress is activated by free fatty acids in cultured human hepatocytes. Metab Syndr Relat Disord 2011; 9: 397-401 [PMID: 21561340 DOI: 10.1089/met.2010.0140]
112. Leach NV, Dronca E, Vesa SC, Sampelean DP, Craciun EC, Lupsor M, Crisan D, Tarau R, Rusu R, Para I, Grigorescu M. Serum homocysteine levels, oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis. Eur J Intern Med 2014; 25: 762-767 [PMID: 25262992 DOI: 10.1016/j.ejim.2014.09.007]
113. Loomba R, Quehenberger O, Armando A, Dennis EA. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. J Lipid Res 2015; 56: 185-192 [PMID: 25404585 DOI: 10.1194/jlr.P055640]
114. Luukkonen PK, Zhou Y, Sädevirta S, Leivonen M, Arola J, Oreŝi? M, Hyötyläinen T, Yki-Järvinen H. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1167-1175 [PMID: 26780287 DOI: 10.1016/j.jhep.2016.01.002]
115. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-S57 [PMID: 25086286 DOI: 10.1016/j.jhep.2014.07.027]
116. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-S68 [PMID: 25443346 DOI: 10.1016/j.jhep.2014.07.012]
117. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, Razavi H, Vickerman P. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16: 797-808 [PMID: 26922272 DOI: 10.1016/S1473-3099(15)00485-5]
118. Aghemo A, Dore GJ, Hatzakis A, Wedemeyer H, Razavi H. Estimating HCV disease burden-volume 3 (editorial). J Viral Hepat 2015; 22 Suppl 4: 1-3 [PMID: 26513444 DOI: 10.1111/jvh.12473]
119. Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol 2016; 64: 1217-1223 [PMID: 27059129 DOI: 10.1016/j.jhep.2016.01.034]
120. Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015; 149: 1345-1360 [PMID: 26319013 DOI: 10.1053/j.gastro.2015.08.035]
121. Lonardo A, Adinolfi LE, Petta S, Craxì A, Loria P. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther 2009; 7: 293-308 [PMID: 19344243 DOI: 10.1586/eri.09.3]
122. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology 2016; 150: 1599-1608 [PMID: 26924097 DOI: 10.1053/j.gastro.2016.02.039]
123. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-1139 [PMID: 7699240]
124. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, O' Rahilly S, Shore S, Tom BD, Alexander GJ. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-1063 [PMID: 10498660 DOI: 10.1002/hep.510300416]
125. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000; 32: 209-217 [PMID: 10707860]
126. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998; 26: 30-33 [PMID: 9492860]
127. Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, Greig PD, Lilly LB, Heathcote JE, Levy GA, Cattral MS. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32: 87-90 [PMID: 10869293 DOI: 10.1053/jhep.2000.8270]
128. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004; 10: 349-355 [PMID: 15004760 DOI: 10.1002/lt.20092]
129. Saliba F, Lakehal M, Pageaux GP, Roche B, Vanlemmens C, Duvoux C, Dumortier J, Salamé E, Calmus Y, Maugendre D. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study. Liver Transpl 2007; 13: 136-144 [PMID: 17192854 DOI: 10.1002/lt.21010]
130. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355-359 [PMID: 10761489 DOI: 10.4065/75.4.355]
131. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, Brun JM, Hillon P. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35: 279-283 [PMID: 11580152]
132. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 1695-1704 [PMID: 14724822]
133. Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 2004; 27: 1171-1175 [PMID: 15111540]
134. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423 [PMID: 18164296 DOI: 10.1053/j.gastro.2007.11.010]
135. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006; 43: 1168; author reply 1168-1169 [PMID: 16628642 DOI: 10.1002/hep.21125]
136. Hsu CS, Liu CJ, Liu CH, Wang CC, Chen CL, Lai MY, Chen PJ, Kao JH, Chen DS. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008; 28: 271-277 [PMID: 18028320 DOI: 10.1111/j.1478-3231.2007.01626.x]
137. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599 [PMID: 11033586]
138. Gray H, Wreghitt T, Stratton IM, Alexander GJ, Turner RC, O'Rahilly S. High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med 1995; 12: 244-249 [PMID: 7538925]
139. Simó R, Hernández C, Genescà J, Jardí R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996; 19: 998-1000 [PMID: 8875096]
140. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-333 [PMID: 9918906 DOI: 10.1002/hep.510290235]
141. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 50-56 [PMID: 12829986 DOI: 10.1053/jhep.2003.50291]
142. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a communitybased longitudinal study. Am J Epidemiol 2007; 166: 196-203 [PMID: 17496314 DOI: 10.1093/aje/kwm061]
143. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831-844 [PMID: 18814931 DOI: 10.1016/j.jhep.2008.08.006]
144. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-1008 [PMID: 15951550 DOI: 10.1136/gut.2004.050302]
145. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509-1515 [PMID: 15984973 DOI: 10.1111/j.1572-0241.2005.41403. x]
146. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, Dufour JF, Helbling B, Hadengue A, Gonvers JJ, Müllhaupt B, Cerny A, Mondelli MU, Negro F. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005; 42: 41-46 [PMID: 15726693]
147. Petta S, Cammà C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, Craxì A. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008; 103: 1136-1144 [PMID: 18477344 DOI: 10.1111/j.1572-0241.2008.01813.x]
148. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, Heimbach JK, Janssen HL, Charlton MR. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406-1413 [PMID: 19459812 DOI: 10.1111/j.1600-6143.2009.02642.x]
149. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-1862 [PMID: 18506898 DOI: 10.1002/hep.22251]
150. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121 [PMID: 18505690 DOI: 10.1053/j.gastro.2008.03.073]
151. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, Lu SN, Lee CM. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010; 16: 2265-2271 [PMID: 20458764]
152. Nkontchou G, Bastard JP, Ziol M, Aout M, Cosson E, Ganne-Carrie N, Grando-Lemaire V, Roulot D, Capeau J, Trinchet JC, Vicaut E, Beaugrand M. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 2010; 53: 827-833 [PMID: 20728234 DOI: 10.1016/j.jhep.2010.04.035]
153. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641 [PMID: 15765399]
154. Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, George J. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28-34 [PMID: 17977612 DOI: 10.1016/j.jhep.2007.07.026]
155. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-718 [PMID: 19231011 DOI: 10.1016/j.jhep.2008.12.017]
156. Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 2014; 20: 3410-3417 [PMID: 24707124 DOI: 10.3748/wjg.v20.i13.3410]
157. Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, Cammà C. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology 2016; 150: 145-155.e4; quiz e15-16 [PMID: 26386298 DOI: 10.1053/j.gastro.2015.09.007]
158. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-576 [PMID: 17222321 DOI: 10.1111/j.1572-0241.2006.01038.x]
159. Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011; 140: 469-477 [PMID: 21070775 DOI: 10.1053/j.gastro.2010.11.002]
160. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739-744 [PMID: 19127513 DOI: 10.1002/hep.22703]
161. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293-1302 [PMID: 24122848 DOI: 10.1002/hep.26892]
162. Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015; 64: 495-503 [PMID: 25398770 DOI: 10.1136/gutjnl-2014-308163]
163. Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol 2013; 19: 6947-6956 [PMID: 24222938 DOI: 10.3748/wjg.v19.i41.6947]
164. Serfaty L, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, Drenth JP, Lonjon-Domanec I, DeMasi R, Picchio G, Beumont M, Marcellin P. Insulin resistance and response to telaprevir plus peginterferon ? and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012; 61: 1473-1480 [PMID: 22387529 DOI: 10.1136/gutjnl-2011-300749]
165. Pavone P, Tieghi T, d'Ettorre G, Lichtner M, Marocco R, Mezzaroma I, Passavanti G, Vittozzi P, Mastroianni CM, Vullo V. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect 2016; 22: 462.e1-462.e3 [PMID: 26812446 DOI: 10.1016/j.cmi.2015.12.030]
166. Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 2015; 61: 790-801 [PMID: 25203718 DOI: 10.1002/hep.27424]
167. Matsumori A, Yutani C, Ikeda Y, Kawai S, Sasayama S. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 2000; 80: 1137-1142 [PMID: 10908160]
168. Boddi M, Abbate R, Chellini B, Giusti B, Solazzo V, Soft F, Pratesi G, Pratesi C, Gensini G, Zignego AL. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis 2007; 39 Suppl 1: S55-S60 [PMID: 17936225]
169. Sanchez MJ, Bergasa NV. Hepatitis C associated cardiomyopathy: potential pathogenic mechanisms and clinical implications. Med Sci Monit 2008; 14: RA55-RA63 [PMID: 18443562]
170. Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, Pratesi G, Rossi L, Pratesi C, Gensini GF, Paperetti L, Zignego AL. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 2010; 47: 72-75 [PMID: 19896417 DOI: 10.1016/j.jcv.2009.10.005]
171. Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol 2014; 20: 7089-7103 [PMID: 24966582 DOI: 10.3748/wjg.v20.i23.7089]
172. Maruyama S, Koda M, Oyake N, Sato H, Fujii Y, Horie Y, Murawaki Y. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol 2013; 58: 11-15 [PMID: 22889957 DOI: 10.1016/j.jhep.2012.07.045]
173. Omran DA, Behairy NH, Zakaria KS, Nabil MM, Said K. Functional and morphological myocardial changes in hepatitis C virus patients with end-stage liver disease. Scand J Gastroenterol 2015; 50: 1135-1143 [PMID: 25716364 DOI: 10.3109/00365521.2 015.1019559]
174. Tomiyama H, Arai T, Hirose K, Hori S, Yamamoto Y, Yamashina A. Hepatitis C virus seropositivity, but not hepatitis B virus carrier or seropositivity, associated with increased pulse wave velocity. Atherosclerosis 2003; 166: 401-403 [PMID: 12535755]
175. Ishizaka N, Ishizaka Y, Takahashi E, Tooda Ei, Hashimoto H, Nagai R, Yamakado M. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359: 133-135 [PMID: 11809259]
176. Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007; 46: 1126-1132 [PMID: 17335930 DOI: 10.1016/j.jhep.2007.01.021]
177. Mostafa A, Mohamed MK, Saeed M, Hasan A, Fontanet A, Godsland I, Coady E, Esmat G, El-Hoseiny M, Abdul-Hamid M, Hughes A, Chaturvedi N. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010; 59: 1135-1140 [PMID: 20584782 DOI: 10.1136/gut.2009.202317]
178. Petta S, Torres D, Fazio G, Cammà C, Cabibi D, Di Marco V, Licata A, Marchesini G, Mazzola A, Parrinello G, Novo S, Licata G, Craxì A. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 2012; 55: 1317-1323 [PMID: 22135089 DOI: 10.1002/hep.25508]
179. Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012; 221: 496-502 [PMID: 22385985 DOI: 10.1016/j.atherosclerosis.2012.01.051]
180. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225-232 [PMID: 19508169 DOI: 10.1086/599371]
181. Lin MS, Guo SE, Chen MY, Huang TJ, Huang JC, Hu JH, Lin YS. The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram. Am J Med Sci 2014; 347: 478-484 [PMID: 24335568 DOI: 10.1097/MAJ.0b013e3182a5587d]
182. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther 2013; 37: 647-652 [PMID: 23384408 DOI: 10.1111/apt.12234]
183. Vassalle C, Masini S, Bianchi F, Zucchelli GC. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004; 90: 565-566 [PMID: 15084562]
184. Alyan O, Kacmaz F, Ozdemir O, Deveci B, Astan R, Celebi AS, Ilkay E. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 2008; 72: 1960-1965 [PMID: 18957787]
185. Satapathy SK, Kim YJ, Kataria A, Shifteh A, Bhansali R, Cerulli MA, Bernstein D. Higher Prevalence and More Severe Coronary Artery Disease in Hepatitis C Virus-infected Patients: A Case Control Study. J Clin Exp Hepatol 2013; 3: 186-191 [PMID: 25755499 DOI: 10.1016/j.jceh.2013.05.004]
186. Pothineni NV, Delongchamp R, Vallurupalli S, Ding Z, Dai Y, Hagedorn CH, Mehta JL. Impact of hepatitis C seropositivity on the risk of coronary heart disease events. Am J Cardiol 2014; 114: 1841-1845 [PMID: 25438910 DOI: 10.1016/j.amjcard.2014.09.020]
187. McKibben RA, Haberlen SA, Post WS, Brown TT, Budoff M, Witt MD, Kingsley LA, Palella FJ, Thio CL, Seaberg EC. A Crosssectional Study of the Association Between Chronic Hepatitis C Virus Infection and Subclinical Coronary Atherosclerosis Among Participants in the Multicenter AIDS Cohort Study. J Infect Dis 2016; 213: 257-265 [PMID: 26216904 DOI: 10.1093/infdis/jiv396]
188. Yelken B, Gorgulu N, Caliskan Y, Elitok A, Cimen AO, Yazici H, Oflaz H, Turkmen A, Sever MS. Association between chronic hepatitis C infection and coronary flow reserve in dialysis patients with failed renal allografts. Transplant Proc 2009; 41: 1519-1523 [PMID: 19545669 DOI: 10.1016/j.transproceed.2009.03.069]
189. Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One 2012; 7: e31527 [PMID: 22363662 DOI: 10.1371/journal.pone.0031527]
190. Adinolfi LE, Restivo L, Guerrera B, Sellitto A, Ciervo A, Iuliano N, Rinaldi L, Santoro A, Li Vigni G, Marrone A. Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis 2013; 231: 22-26 [PMID: 24125405 DOI: 10.1016/j.atherosclerosis.2013 .08.003]
191. Hsu CS, Kao JH, Chao YC, Lin HH, Fan YC, Huang CJ, Tsai PS. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 2013; 38: 415-423 [PMID: 23802888 DOI: 10.1111/apt.12391]
192. Karibe H, Niizuma H, Ohyama H, Shirane R, Yoshimoto T. Hepatitis C virus (HCV) infection as a risk factor for spontaneous intracerebral hemorrhage: hospital based case-control study. J Clin Neurosci 2001; 8: 423-425 [PMID: 11535009 DOI: 10.1054/jocn.2001.0811]
193. Tseng CH, Muo CH, Hsu CY, Kao CH. Increased Risk of Intracerebral Hemorrhage Among Patients With Hepatitis C Virus Infection. Medicine (Baltimore) 2015; 94: e2132 [PMID: 26579831 DOI: 10.1097/MD.0000000000002132]
194. Hsu YH, Muo CH, Liu CY, Tsai WC, Hsu CC, Sung FC, Kao CH. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study. J Hepatol 2015; 62: 519-525 [PMID: 25263004 DOI: 10.1016/j.jhep.2014.09.022]
195. Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, Busch MP, Murphy EL. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167: 743-750 [PMID: 18203734 DOI: 10.1093/aje/kwm370]
196. Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, You SL, Chen WJ, Chen CJ. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41: 2894-2900 [PMID: 20966408 DOI: 10.1161/STROKEAHA.110.598136]
197. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a communitybased long-term prospective study. J Infect Dis 2012; 206: 469-477 [PMID: 22811301 DOI: 10.1093/infdis/jis385]
198. Fernández-Montero JV, Barreiro P, de Mendoza C, Labarga P, Soriano V. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat 2016; 23: 47-52 [PMID: 26390144 DOI: 10.1111/jvh.12447]
199. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012; 19: 601-607 [PMID: 22863263 DOI: 10.1111/j.1365-2893.2012.01633.x]
200. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014; 61: S69-S78 [PMID: 25443347 DOI: 10.1016/j.jhep.2014.08.003]
201. Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Dig Liver Dis 2016; 48: 105-111 [PMID: 26614641 DOI: 10.1016/j.dld.2015.10.016]
202. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol 2008; 82: 2606-2612 [PMID: 18160431 DOI: 10.1128/JVI.01672-07]
203. Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother 2011; 12: 2215-2234 [PMID: 21883025 DOI: 10.1517/14656566.2011.597742]
204. Jepsen P, Watson H, Andersen PK, Vilstrup H. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients. J Hepatol 2015; 63: 1133-1138 [PMID: 26206073 DOI: 10.1016/j.jhep.2015.07.007]
205. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016; 64: 130-137 [PMID: 26946190 DOI: 10.1002/hep.28535]
206. Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol 2015; 13: 2140-2151 [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014]
207. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2012; 61: 128-134 [PMID: 21873466 DOI: 10.1136/gut.2010.236158]
208. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364 [PMID: 11391523 DOI: 10.1053/jhep.2001.24432]
209. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85 [PMID: 12829989 DOI: 10.1053/jhep.2003.50267]
210. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006; 13: 73-80 [PMID: 16436124 DOI: 10.1111/j.1365-2893.2005.00669.x]
211. Global-AIDS-update-2016-en.pdf [Internet]. unaids.org [cited 2016-06-30]. Available from: URL: http://wwwunaidsorg/sites/default/files/media-asset/global-AIDS-update-2016-enpdf
212. Sabin CA. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med 2013; 11: 251 [PMID: 24283830 DOI: 10.1186/1741-7015-11-251]
213. Greene M, Justice AC, Lampiris HW, Valcour V. Management of human immunodeficiency virus infection in advanced age. JAMA 2013; 309: 1397-1405 [PMID: 23549585 DOI: 10.1001/jama.2013.2963]
214. De Cock KM, El-Sadr WM, Ghebreyesus TA. Game changers: why did the scale-up of HIV treatment work despite weak health systems? J Acquir Immune Defic Syndr 2011; 57 Suppl 2: S61-S63 [PMID: 21857297 DOI: 10.1097/QAI.0b013e3182217f00]
215. Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, Paredes R, Bakowska E, Engsig FN, Phillips A. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27: 973-979 [PMID: 23698063 DOI: 10.1097/QAD. 0b013e32835cae9c]
216. Cooperman NA, Arnsten JH, Klein RS. Current sexual activity and risky sexual behavior in older men with or at risk for HIV infection. AIDS Educ Prev 2007; 19: 321-333 [PMID: 17685845 DOI: 10.1521/aeap.2007.19.4.321]
217. Guaraldi G, Zona S, Brothers TD, Carli F, Stentarelli C, Dolci G, Santoro A, Beghetto B, Menozzi M, Mussini C, Falutz J. Aging with HIV vs. HIV seroconversion at older age: a diverse population with distinct comorbidity profiles. PLoS One 2015; 10: e0118531 [PMID: 25874806 DOI: 10.1371/journal.pone.0118531]
218. Guaraldi G, Orlando G, Squillace N, De Santis G, Pedone A, Spaggiari A, De Fazio D, Vandelli M, De Paola M, Bertucelli C, Aldrovandi C, Nardini G, Beghetto B, Borghi V, Bertolotti M, Bagni B, Grazia Amorico M, Roverato A, Esposito R. Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy. HIV Clin Trials 2006; 7: 97-106 [PMID: 16880166 DOI: 10.1310/EYWJ-8B5K-X7VQ-9CPE]
219. Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep 2012; 9: 206-217 [PMID: 22752405 DOI: 10.1007/s11904-012-0124-x]
220. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB, Dobs AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179-1184 [PMID: 15911733 DOI: 10.1001/archinte.165.10.1179]
221. Reingold J, Wanke C, Kotler D, Lewis C, Tracy R, Heymsfield S, Tien P, Bacchetti P, Scherzer R, Grunfeld C, Shlipak M. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48: 142-148 [PMID: 18344877 DOI: 10.1097/QAI.0b013e3181685727]
222. Stankov MV, Behrens GM. Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients. Curr Pharm Des 2010; 16: 3361-3371 [PMID: 20687889]
223. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107 [PMID: 21233852 DOI: 10.1038/nri2925]
224. Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011; 56: 36-43 [PMID: 20930640 DOI: 10.1097/QAI.0b013e3181f7f61a]
225. Feeney ER, Mallon PW. Insulin resistance in treated HIV infection. Best Pract Res Clin Endocrinol Metab 2011; 25: 443-458 [PMID: 21663838 DOI: 10.1016/j.beem.2010.11.002]
226. Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC, Witte DR. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32: 421-423 [PMID: 19073760 DOI: 10.2337/dc08-1161]
227. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47 [PMID: 10880413]
228. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997; 82: 4167-4170 [PMID: 9398733 DOI: 10.1210/jcem.82.12.4422]
229. Béténé A Dooko C, De Wit S, Neuhaus J, Palfreeman A, Pepe R, Pankow JS, Neaton JD. Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIVpositive patients taking antiretroviral therapy. J Acquir Immune Defic Syndr 2014; 67: 538-546 [PMID: 25393940 DOI: 10.1097/QAI.0000000000000354]
230. Zanni MV, Schouten J, Grinspoon SK, Reiss P. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol 2014; 11: 728-741 [PMID: 25331088 DOI: 10.1038/nrcardio.2014.167]
231. Paisible AL, Chang CC, So-Armah KA, Butt AA, Leaf DA, Budoff M, Rimland D, Bedimo R, Goetz MB, Rodriguez-Barradas MC, Crane HM, Gibert CL, Brown ST, Tindle HA, Warner AL, Alcorn C, Skanderson M, Justice AC, Freiberg MS. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr 2015; 68: 209-216 [PMID: 25588033 DOI: 10.1097/QAI.0000000000000419]
232. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, Rimland D, Rodriguez Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-622 [PMID: 23459863 DOI: 10.1001/jamainternmed.2013.3728]
233. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512 [PMID: 17456578 DOI: 10.1210/jc.2006-2190]
234. Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker S, Porter K, Sabin C, Chêne G. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23: 1743-1753 [PMID: 19571723 DOI: 10.1097/QAD.0b013e32832e9b78]
235. Baker JV, Peng G, Rapkin J, Abrams Di, Silverberg MJ, MacArthur RD, Cavert WP, Henry WK, Neaton JD. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22: 841-848 [PMID: 18427202 DOI: 10.1097/QAD.0b013e3282f7cb76]
236. Debaisieux S, Rayne F, Yezid H, Beaumelle B. The ins and outs of HIV-1 Tat. Traffic 2012; 13: 355-363 [PMID: 21951552 DOI: 10.1111/j.1600-0854.2011.01286.x]
237. Dhawan S, Puri RK, Kumar A, Duplan H, Masson JM, Aggarwal BB. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood 1997; 90: 1535-1544 [PMID: 9269771]
238. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-4225 [PMID: 9416885]
239. Puppo F, Brenci S, Scudeletti M, Lanza L, Bosco O, Indiveri F. Elevated serum levels of circulating intercellular adhesion molecule-1 in HIV infection. AIDS 1993; 7: 593-594 [PMID: 8099491]
240. Paladugu R, Fu W, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C. Hiv Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2003; 38: 549-555; discussion 555-556 [PMID: 12947275]
241. Shikuma CM, Barbour JD, Ndhlovu LC, Keating SM, Norris PJ, Budoff M, Parikh N, Seto T, Gangcuangco LM, Ogata-Arakaki D, Chow D. Plasma monocyte chemoattractant protein-1 and tumor necrosis factor-? levels predict the presence of coronary artery calcium in HIV-infected individuals independent of traditional cardiovascular risk factors. AIDS Res Hum Retroviruses 2014; 30: 142-146 [PMID: 23984974 DOI: 10.1089/AID.2013.0183]
242. Kedzierska K, Crowe SM. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr Med Chem 2002; 9: 1893-1903 [PMID: 12369874]
243. Palmer CS, Anzinger JJ, Zhou J, Gouillou M, Landay A, Jaworowski A, McCune JM, Crowe SM. Glucose transporter 1-expressing proinflammatory monocytes are elevated in combination antiretroviral therapy-treated and untreated HIV+ subjects. J Immunol 2014; 193: 5595-5603 [PMID: 25367121 DOI: 10.4049/jimmunol.1303092]
244. Zanni MV, Abbara S, Lo J, Wai B, Hark D, Marmarelis E, Grinspoon SK. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS 2013; 27: 1263-1272 [PMID: 23324657 DOI: 10.1097/QAD.0b013e32835eca9b]
245. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, Corsini E, Abdelbaky A, Zanni MV, Hoffmann U, Williams KC, Lo J, Grinspoon SK. Arterial inflammation in patients with HIV. JAMA 2012; 308: 379-386 [PMID: 22820791 DOI: 10.1001/jama.2012.6698]
246. Chakko S, Myerburg RJ. Cardiac complications of cocaine abuse. Clin Cardiol 1995; 18: 67-72 [PMID: 7720292]
247. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000; 30 Suppl 2: S135-S142 [PMID: 10860898 DOI: 10.1086/313854]
248. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010; 52: 71-78 [PMID: 20578130 DOI: 10.1002/hep.23619]
249. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, Palella F. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47: 250-257 [PMID: 18532884 DOI: 10.1086/589294]
250. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, Goodman Z, Parker R, Lifson A, Capozza T, Bavaro M, Hale B, Hames C. Nonalcoholic fatty liver disease among HIVinfected persons. J Acquir Immune Defic Syndr 2009; 50: 464-473 [PMID: 19225402 DOI: 10.1097/QAI.0b013e318198a88a]
251. Castéra L, Loko MA, Le Bail B, Coffie P, De Ledinghen V, Trimoulet P, Winnock M, Dabis F, Neau D. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. Aliment Pharmacol Ther 2007; 26: 1489-1498 [PMID: 17903235 DOI: 10.1111/j.1365-2036.2007.03533.x]
252. Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, Torbenson MS, Moore RD, Sulkowski MS. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140: 809-817 [PMID: 21134375 DOI: 10.1053/j.gastro.2010.11.052]
253. McGovern BH. Hepatic steatosis in HIV/HCV-coinfected patients: time to reevaluate. Gastroenterology 2011; 140: 772-775 [PMID: 21276415 DOI: 10.1053/j.gastro.2011.01.025]
254. Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIVassociated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther 2015; 41: 368-378 [PMID: 25496369 DOI: 10.1111/apt.13052]
255. Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol 2011; 8: 11-21 [PMID: 21931374 DOI: 10.1038/nrendo.2011.151]
256. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007; 357: 2359-2370 [PMID: 18057338 DOI: 10.1056/NEJMoa072375]
257. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 2014; 312: 380-389 [PMID: 25038357 DOI: 10.1001/jama.2014.8334]
258. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-597 [PMID: 14762795]
259. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62: S47-S64 [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012]
260. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-871 [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044]
261. European Association for the Study of Obesity (EASO). EASLEASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]
262. Nix LM, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr HIV/AIDS Rep 2014; 11: 271-278 [PMID: 25027062 DOI: 10.1007/s11904-014-0219-7]
263. Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J 2014; 35: 1373-1381 [PMID: 24408888 DOI: 10.1093/eurheartj/eht528]
264. Vallet-Pichard A, Mallet V, Pol S. Nonalcoholic fatty liver disease and HIV infection. Semin Liver Dis 2012; 32: 158-166 [PMID: 22760655 DOI: 10.1055/s-0032-1316471]